Postmarketing Study of Empliciti in Korean Patients With Multiple Myeloma

Bristol-Myers Squibb (BMS)

Status: Withdrawn

Conditions: Multiple Myeloma

Treatments: Other: Non-Interventional

Study type: Observational

Funder types: Industry

Identifiers

NCT03660072

CA204-176

Details and patient eligibility

About

This study is a regulatory postmarketing surveillance study for Empliciti with a representative sample of the overall Korean multiple myeloma (MM) population.

Sex: All

Ages: 19+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adult participants who have a confirmed diagnosis of Multiple Myeloma (MM)

Exclusion criteria

• Participants who use Empliciti for therapeutic indications which are not approved for Empliciti combination therapy in Korea
• Patients in whom treatment with Empliciti (as clarified in the Korean label) is contraindicated

Other protocol defined inclusion/exclusion criteria could apply

Trial design

0 participants in 1 patient group

Empliciti combination therapy

Description:

Adult patients with a confirmed diagnosis of MM who have received, are currently receiving, or will begin Empliciti combination therapy

Treatment:

Other: Non-Interventional